drugset
drugset / Trial / NCT00549328

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

NCT00549328 ↗

Phase 2 Terminated 14 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate the efficacy and safety of monotherapy pazopanib (a small molecule tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit) in subjects with advanced (Stage IIIB or IV) non-small cell lung cancer.

Timeline

Start
2008-02
Primary completion
2009-04
Completion
2009-04

Outcome

Outcome not reported

Stopped: “Study enrolment was delayed in starting and too slow to support further development in this setting”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule 800 mg Oral

Indications

non-small cell lung carcinoma